Click on image to view larger version.

Figure 1 Comparison of bivalirudin with provisional glycoprotein (GP) IIb/IIIa blockade versus heparin with routine GP IIb/IIIa blockade with respect to the primary composite end point of death, myocardial infarction, urgent revascularization, and in-hospital major bleeding by 30 days in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to reduced Clinical Events (REPLACE-2) trial.